pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,099 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1863Endpoints1446Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls119
therapy area
allOncology12886Rare Disease3335Immunology3022Cardiology2847Hematology2298Pulmonology2253Vaccines
  • American expatriate in Malta finds free health care but misses digital patient portal
    Mariska Breland, an American co‑founder of The Neuro Studio, moved to Malta seeking free health care and recounts her first visit to a local general practitioner. She describes a modest clinic wit…
    STAT · 14d agoNeutral↗ source
  • AbbVie bets up to $1.47B for Nxera’s discarded IBD program
    AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
    BioSpace · 14d ago↗ source
  • Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trial
← prev
page 14 of 124
next →
fda medwatch114
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1133
Endocrinology & Metabolism807
Pain791
Nephrology783
Servier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…
STAT · 15d agoNegative readoutNegative↗ source
  • Neurocrine launches new safety study after another death linked to Prader-Willi drug Vykat
    Neurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…
    BioSpace · 15d agoRegulatoryNegative↗ source
  • Scientists question safety and benefits of three-parent IVF as new UK data raise concerns
    The mitochondrial replacement technique, often called three‑parent IVF, was hailed after the United Kingdom reported the birth of eight healthy children whose mothers carried disease‑causing mitoch…
    STAT · 15d agoRegulatoryNegative↗ source
  • Compact Medical issues recall and updated instructions for ButterflyBVM bag-valve-mask resuscitators due to bellows holes
    The FDA's Center for Devices and Radiological Health has issued an early alert about a potential high‑risk problem with certain Compact Medical ButterflyBVM bag‑valve‑mask devices. Compact Medical…
    fda medwatch · 15d agoCRLNegative↗ source
  • MGB CEO's vague email on financial challenges fuels anxiety after recent layoffs
    Mass General Brigham chief executive Dr. Anne Klibanski emailed the system’s roughly 85,000 staff late Monday, warning of urgent financial challenges and a need to improve performance. The message…
    STAT · 15d agoLayoffsNegative↗ source
  • Pfizer partners with Sciwind to launch GLP-1 obesity drug Ecnoglutide in China
    Pfizer is entering China's obesity market with a new GLP-1 drug, Ecnoglutide, in partnership with Sciwind Biosciences. The New York-based company secured mainland China licensing rights to the inj…
    BioSpace · 15d agoDealPositive↗ source
  • Lonza to acquire five Merck KGaA US facilities, more than doubling its US footprint
    Lonza, a Swiss contract development and manufacturing organization, announced it will purchase five U.S. manufacturing sites from Merck KGaA. The transaction is valued in the low‑ to mid‑triple‑di…
    BioSpace · 15d agoDealPositive↗ source
  • FDA grants tentative approval for Dr. Reddy’s generic HIV prevention shot, expanding access in low- and middle-income countries
    The U.S. Food and Drug Administration has issued a tentative approval for Dr. Reddy’s Laboratories to produce a generic version of a leading HIV prevention medicine. This decision follows months of…
    STAT · 15d agoApprovalPositive↗ source
  • Novartis ends $772M BioArctic brain-delivery partnership
    Novartis has terminated its neurodegeneration alliance with BioArctic, a partnership that was valued at more than $772 million. The collaboration focused on using BioArctic’s BrainTransporter techn…
    BioSpace · 15d agoDealNegative↗ source
  • Pfizer reports flat Q3 revenue as non-COVID sales rise 7% and acquired products grow 32%
    Pfizer posted third‑quarter revenue of $16.6 billion, essentially unchanged from $16.7 billion a year earlier. The flat top line reflects declines in its legacy Prevnar vaccine and COVID‑related pr…
    BioSpace · 15d agoEarningsNeutral↗ source
  • New York records first measles death in three decades as vaccination rates slip
    A child in rural northern New York died after contracting measles, marking the first measles-related death in the state in 30 years, officials said. The death comes as U.S. vaccination coverage ha…
    STAT · 15d agoNegative↗ source
  • First U.S. bird flu death of 2026 reported in Washington state after cattle exposure
    A person in Washington state died from complications of avian influenza, according to the Associated Press. It is the first bird flu death in the United States this year. The case follows recent r…
    STAT · 15d agoNegative↗ source
  • Legal experts advise European healthcare manufacturers on navigating complex environmental regulations
    At the RAPS Regulatory Intelligence Conference Europe in Barcelona, two legal specialists highlighted the difficulty of Europe’s environmental and sustainability rules for companies that make healt…
    raps · 15d agoRegulatoryNeutral↗ source
  • FDA reports rise in unannounced drug inspections in China and India for FY 2026
    A senior FDA enforcement official said the agency carried out more surprise drug facility inspections in India and China during fiscal year 2026 than it did in the prior year. The unannounced visi…
    raps · 15d agoRegulatoryNeutral↗ source
  • Compass Pathways leads race for first psychedelic drug approval, non-profit rivals
    Compass Pathways is widely viewed as a leading candidate to bring the first psychedelic medicine to market. The company has advanced its therapy through clinical development and is positioned near…
    STAT · 15d agoNeutral↗ source
  • Stakeholders submit over 500 comments urging FDA to shape regulation of generative AI medical devices
    Over 500 comments have been filed in response to the FDA's discussion paper on generative AI-enabled medical devices. The feedback reflects a wide range of viewpoints. Some participants recommend…
    raps · 15d agoRegulatoryNeutral↗ source
  • Midterm elections could reshape health policy, Medicare Advantage and insurance, STAT analysis says
    STAT's D.C. Diagnosis newsletter looks at how the upcoming midterm elections may influence health policy, Medicare Advantage programs and health insurance markets. With record early voting turnout…
    STAT · 15d agoNeutral↗ source
  • FDA and CMS seek state partnerships to shape health AI regulations and liability protections
    The Food and Drug Administration and the Centers for Medicare & Medicaid Services are planning to work with state governments to develop coordinated rules for artificial intelligence used in health…
    STAT · 15d agoRegulatoryNeutral↗ source
  • Mortality rates remain higher in states that supported Trump, highlighting political health divide in 2024
    The UCSF team behind the article notes that health care ranks as the third most important issue for voters in the 2026 midterm election cycle. They found that, after adjusting for age differences,…
    STAT · 15d agoNeutral↗ source
  • Physician finds meditation boosts resilience and patient care after intense trauma cases
    The author, an ophthalmologist at Legacy Devers Eye Institute, attended a meditation retreat in the Santa Cruz Mountains last fall. He describes staying awake through dawn as part of the retreat,…
    STAT · 15d agoPositive↗ source
  • Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcy
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 15d ago↗ source
  • FDA grants tentative approval for generic HIV prevention shot, boosting access in low-income nations
    After months of anticipation, the U.S. Food and Drug Administration issued a tentative approval for Dr. Reddy’s Laboratories to produce a generic version of lenacapavir, the long‑acting injectable…
    STAT · 16d agoRegulatoryPositive↗ source
  • FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory saga
    The U.S. Food and Drug Administration has accepted uniQure's biologics license application for its Huntington's disease gene therapy and placed it on the priority review track, with a May 1 target…
    BioSpace · 16d agoRegulatoryPositive↗ source